Navigation Links
Roche offers HIV drug expertise to poor nations

Swiss pharmaceutical giant Roche announced transfer technology to generic drug manufacturers in the least developed countries and sub-Saharan Africa// to produce versions of the HIV drug saquinavir.

As part of its new Technology Transfer Initiative, Roche has announced further expansion of its current activities within sub-Saharan Africa and the world's Least Developed Countries by providing local manufacturers with the technical expertise for producing generic HIV medicines.

These countries are home for 69 percent of the HIV/AIDS population in the world.

Saquinavir is a protease inhibitor, one of a class of drugs that work by blocking part of the virus and preventing it from replicating itself.

Protease inhibitors are used in combination with other anti-HIV drugs in so-called treatment cocktails, which aim to reduce the amount of HIV in the body.

AIDS campaigners have been pushing drug companies to offer second-line treatment at lower prices, following discounts offered on the first-line products.

Roche said it would make its HIV protease inhibitors Invirase and Viracept available at no-profit prices for direct supplies from Roche Basel to LDCs and sub-Saharan Africa.

The transfer of expertise model will be based on the processes to manufacture saquinavir, the HIV protease inhibitor medicine recommended by the World Health Organization as a second line treatment in resource-limited settings.

William M. Burns, CEO Division Roche Pharmaceuticals, said, "With international funding now available, Africa will be the world's biggest user of HIV medicine. We have taken this unique step to help ensure that the right medicines in the right formulation are locally available. We want to use the knowledge we have developed to help strengthen local manufacturing capability and hope to help as many manufacturers as possible in these hardest hit countries by sharing our knowledge, so that they can l
'"/>




Page: 1 2

Related medicine news :

1. FDA Imposes New Restrictions On Roches Accutane
2. Roche confirms Tamiflu production talks in US
3. Roche Commits More Antiviral Pills To Asia For Bird Flu
4. Distinguished Scientist Award Conferred on University of Rochester Scientists for Work on Preventing Cavities
5. Roche Rolls Out Lung Cancer Drug In India
6. New Lung Cancer Drug Launched By Roche Pharmaceutical
7. Roche Calls For Re-Examination Of Tarceva Data By EU Authorities
8. Roche puts in an Application to Use Herceptin for Treatment in Her-2 positive breast cancer
9. NICE Gives the Final ‘NO’ to Roche’s Tarcva
10. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
11. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
Post Your Comments:
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...Harvard and McGill Universities are experimenting ...bad memories, while leaving the rest of their memo...anolol along with therapy to "dampen" memories of ... days. They asked the patients to describe their m...
...wooden Al Gore, former US vice president and prese...ng alive, almost literally, across the world Satur... series of concerts of pop and rock music featurin...Saturday July 7, 2007 to promote action to confron...
... must remain vigilant against deadly bird flu sinc...th agency official said on Tuesday. "I think cou...o fight the virus. But in spite of it, the virus i...aid Shigeru Omi, WHO's regional director for the W...
...orts clubs do not run regular comprehensive health...d ahead of print in the British Journal of Sports ...s from 65 professional clubs, covering football (p...ship), rugby (union and league), and County cricke...
Other Medicine News:Health News:Live Earth Will Make the World More Aware of the Crisis Facing the Earth, Hopes Al Gore 2Health News:Live Earth Will Make the World More Aware of the Crisis Facing the Earth, Hopes Al Gore 3Health News:Bird Flu in Asia Still High Risk Says WHO Official 2Health News:UK Sports Clubs Failing to Run Comprehensive Health Checks on Professional Players 2
(Date:9/4/2008)... BIRMINGHAM, Ala., Sept. 4 /- Souther...onal Institutes of Health (NIH) has selected,the o...ecular Libraries,Probe Production Center Network (...ork -- is part of the Molecular Libraries Program ... scientific knowledge of the human,genome and vali...
(Date:9/4/2008)...00 mg cohort demonstrates potent antiviral activit... profile -, CAMBRIDGE, Mass., Sept. 4 /PRNewswi...daq: IDIX ), a biopharmaceutical company engaged,...treatment of human viral,and other infectious dise...oof-of-concept study evaluating IDX899, a non-nucl...
(Date:9/3/2008)...NAA says: Wrong Question Asked. Wrong Children Stu.... 3 /PRNewswire-USNewswire/ -- A Centers for Disea...ay claims there is no link,between the MMR vaccine...,says this study does nothing to dispel the growin...and raises several questions concerning design,and...
(Date:9/3/2008)... September is National Vascular Disease Awa...wswire/ -- Diffusion Pharmaceuticals,LLC, a clinic...new drugs,for the treatment of unmet medical needs...ents in a Phase I/II clinical trial of its lead dr...rial, designated NCT00725881,on the clinicaltrials...
Breaking Medicine Technology:Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4CDC Misses Target With Flawed MMR/Autism Study 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Treating rare breast cancer with radiation therapy may lower recurrence rate 23815 1Treating rare breast cancer with radiation therapy may lower recurrence rate 23815 2Houston Based Tyrell Inc Completes 2428 Million Private Equity Financing 23810 1Houston Based Tyrell Inc Completes 2428 Million Private Equity Financing 23810 2Houston Based Tyrell Inc Completes 2428 Million Private Equity Financing 23810 3Chindex International Inc Announces CDC Contract Signing 23805 1Chindex International Inc Announces CDC Contract Signing 23805 2Chindex International Inc Announces CDC Contract Signing 23805 3Chindex International Inc Announces CDC Contract Signing 23805 4Signalife Board Approves Merger 6512 1Signalife Board Approves Merger 6512 2Signalife Board Approves Merger 6512 3
...swire-FirstCall/ - AEterna,Zentaris Inc. , a globa...endocrine therapy and oncology, today announced th...n vitro data on its,PI3K inhibitors as well as in ...oth may potentially provide new therapeutic,approa...will be,presented at the American Association for ...
...uce the risk of cancer,returning after surgery for...T) , * Patients receiving placebo in this trial wi...missions planned for use of Glivec as,adjuvant the...primary tumor , * Glivec already approved as effec... or inoperable Kit-positive GIST , BASEL, Switzerl...
Other Medicine Technology:AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors,and In Vivo Results for a GHRH Antagonist at the AACR Annual,Meeting in Los Angeles 2AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors,and In Vivo Results for a GHRH Antagonist at the AACR Annual,Meeting in Los Angeles 3Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 2Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 3Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 4Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 5Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 6
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag.
This unit is the finest standalone handswitch bipolar unit available.
Adson Burr
Hudson Burr
Medicine Products: